Wirth is the CEO of Amida Care. Crowley is the director of the O’Neill Institute’s Center for HIV and Infectious Disease Policy at Georgetown Law. In June, a clinical trial showed that a twice-yearly ...

Prefer Newsweek on Google to see more of our trusted coverage when you search. A new pre-exposure prophylaxis (PrEP) drug has shown promise as a once-monthly oral pill to help prevent HIV. PrEP plays ...

Daily oral PrEP (generic Truvada; Descovy) is effective but adherence-sensitive, and seroconversions in trials correlate with ...

The Centers for Disease Control and Prevention (CDC) has come out with a strong recommendation for the use of Gilead Sciences’ twice-yearly HIV pre-exposure prophylaxis (PrEP) med Yeztugo, ...

Add Yahoo as a preferred source to see more of our stories on Google. HIV/AIDS activists heralded the approval of a new twice-yearly pre-exposure prophylaxis (PrEP) medication last year, but these ...

Lenacapavir, a twice-yearly injectable HIV-1 capsid inhibitor, has shown 100% efficacy in preventing HIV in women at a high risk for infection, according to an interim analysis of the phase 3 PURPOSE ...

Advances in treatment of HIV have improved the health and quality of life for so many. Advances in treatment of the disease have improved the health and quality of life for countless individuals.

Deploying lenacapavir will require rethinking who delivers HIV prevention, how it is financed, and what policy infrastructure ...

HIV prevention doesn’t have to be scary, confusing, or even expensive. Thanks to Mistr, a gay-owned and operated online platform, protecting yourself just got a whole lot easier! Mistr works with real ...

More than four decades into the HIV epidemic, progress has transformed treatment and prevention, yet the need remains urgent.

HIV/AIDS activists heralded the approval of a new twice-yearly pre-exposure prophylaxis (PrEP) medication last year, but these celebrations were tempered by insurers’ reluctance to cover its ...